Citius Pharma Files 8-K on Financial Condition and Operations
Ticker: CTXR · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1506251
Sentiment: neutral
Topics: 8-K Filing, Corporate Update, Financial Disclosure
TL;DR
Citius Pharma just filed an 8-K about their financials, but the specific details aren't in this snippet.
AI Summary
Citius Pharmaceuticals, Inc. filed an 8-K on February 15, 2024, reporting an event that occurred on February 14, 2024. The filing, under Commission File Number 001-38174, indicates it includes information regarding 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. The company is incorporated in Nevada and has its business address in Cranford, NJ.
Why It Matters
This 8-K signals Citius Pharmaceuticals, Inc. is providing an update on its financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — The filing itself is a standard disclosure and does not inherently present a high risk, as the substantive financial details are not provided in this snippet.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — registrant
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is Citius Pharmaceuticals, Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 14, 2024.
In which state or jurisdiction is Citius Pharmaceuticals, Inc. incorporated?
Citius Pharmaceuticals, Inc. is incorporated in Nevada.
What is the Commission File Number for Citius Pharmaceuticals, Inc.?
The Commission File Number is 001-38174.
What specific items are reported under ITEM INFORMATION in this 8-K filing?
The items reported under ITEM INFORMATION are 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-02-15 08:45:11
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value CTXR The Nasdaq Capital M
Filing Documents
- ea193774-8k_citius.htm (8-K) — 25KB
- ea193774ex99-1_citius.htm (EX-99.1) — 76KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001213900-24-014332.txt ( ) — 300KB
- ctxr-20240214.xsd (EX-101.SCH) — 3KB
- ctxr-20240214_lab.xml (EX-101.LAB) — 33KB
- ctxr-20240214_pre.xml (EX-101.PRE) — 22KB
- ea193774-8k_citius_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 14, 2024, we issued a press release announcing our results of operations for the first quarter of fiscal 2024. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated February 14, 2024. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: February 15, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2